FHTX 4.64 ▲ 2.20% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Foghorn Therapeutics Inc.

    NASDAQ: FHTX · Real-Time Price · USD
    4.64
    0.10 (2.20%)
    At close: Oct 03, 2025, 3:59 PM
    4.81
    3.66%
    After-hours: Oct 03, 2025, 05:57 PM EDT
    2.20%
    Bid 3.42
    Market Cap 262.3M
    Revenue (ttm) 24.17M
    Net Income (ttm) -75.39M
    EPS (ttm) -1.14
    PE Ratio (ttm) -4.07
    Forward PE -4.05
    Analyst Buy
    Dividends n/a
    Ask 5.99
    Volume 138,736
    Avg. Volume (20D) 111,622
    Open 4.54
    Previous Close 4.54
    Day's Range 4.54 - 4.76
    52-Week Range 2.94 - 9.70
    Beta 3.03
    Ex-Dividend Date n/a

    About FHTX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol FHTX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for FHTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Foghorn Therapeutics Inc. is scheduled to release its earnings on Nov 3, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    9 months ago
    +3.96%
    Foghorn Therapeutics shares rare trading lower aft... Unlock content with Pro Subscription
    news image

    1 month ago · zacks.com

    Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know

    The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

    news image

    1 month ago · zacks.com

    Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why

    Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · zacks.com

    Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing

    Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou...

    news image

    2 months ago · zacks.com

    Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates

    Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago.

    Add to Watchlist